Family Medicine

Phase III trial shows that transplanted purified human pancreatic islets safely restored sustained near-normoglycemia and provided protection from severe hypoglycemia in patients with long-standing type 1 diabetes and iatrogenic hypoglycemia.

Researchers find that the ratio of total cholesterol to HDL is a significant predictor for CVD in type 1 diabetes patients who are not using lipid-lowering drugs, and that the ratio of total cholesterol to HDL is a more reliable marker for risk when considering primary prevention.

Researchers have identified a previously unrecognized mechanism for SGLT2 inhibitors in the regulation of glucagon and gluconeogenic gene expression.

Most children with hepatitis C contract the virus through transmission from their chronically infected mothers, either in the womb or at birth, particularly when an expectant mother also is HIV-positive.

Patients with type 1 diabetes who had more depressive symptoms measured at baseline and over time appear to be at an increased risk of mortality, even after allowing for likely mediators.

The FDA has granted priority review for a New Drug Application submitted by AbbVie Inc. for its all-oral, interferon-free therapy for patients with chronic genotype 1 hepatitis C virus infection.

By blocking a key pain receptor in mice models, a team of researchers has discovered a potential new method for treating obesity and diabetes.

Older men who take statins reported lower levels of physical activity than nonusers, according to a new study.

Patients with type 2 diabetes and inadequate glycemic control treated with dapagliflozin plus metformin and sulfonylurea experienced sustained improvements in HbA1c, fasting plasma glucose, weight loss, and systolic blood pressure over 52 weeks.

Patients between the ages of 55 and 80 with type 2 diabetes treated with canagliflozin for more than 100 weeks experienced significant reductions in HbA1C, fasting plasma glucose, bodyweight, and systolic blood pressure.

Study results show long-term treatment with empagliflozin was well tolerated and associated with reductions in HbA1c, bodyweight, and systolic blood pressure compared with placebo and sitagliptin.

A single accreditation standard for graduate medical education in the United States will not only bolster training programs for MDs and DOs, but also improve patient care.

To decrease the rates of obesity and type 2 diabetes mellitus (T2DM), a recent study has recommended a ban on sugar-sweetened drinks among food stamp recipients and endorsed an incentive program to encourage healthier eating habits.

Study results presented at ADA 2014 show combination treatment with metformin plus linagliptin delivered consistent HbA1c reductions across different subgroups of patients newly diagnosed with type 2 diabetes, with decreased risk of hypoglycemia.

In response to the growing prevalence of gestational diabetes mellitus and its associated morbidities, much attention has been paid to the use of appropriate screening methodologies for the metabolic disorder.

Study results show that an alternative to currently-marketed injectable agents retains the efficacy of GLP-1 mimetics, while reducing gastrointestinal adverse events and providing the convenience of oral dosing.

Results from the largest population-based, case-control study on the link between incretin therapy and pancreatitis conducted to date indicate that treatment with this class of medications does not confer increased risk of developing pancreatitis.

Combination treatment with insulin degludec and liraglutide was associated with long-term reductions in HbA1c, reduced hypoglycemia risk, and fewer gastrointestinal side effects compared to treatment with the individual medications alone in patients with diabetes.

Patients treated with a new, more concentrated insulin glargine formulation experienced similar glycemic control with fewer nocturnal and daytime hypoglycemic events compared with patients treated with the current formulation of the product.

Study results presented at ADA 2014 show Eli Lilly's investigational long-acting basal insulin analog to have similar clinical efficacy in reducing HbA1c levels as a currently approved injectable insulin glargine product, with a comparable side effect profile.

The US Food and Drug Administration partially lifted a clinical hold on a hepatitis C drug under development by Achillion Pharmaceuticals, clearing the way for a restart of the company's clinical trials of sovaprevir.

Opexa Therapeutics is initiating a phase IIb trial of a novel therapy that targets T-cells in patients with secondary progressive multiple sclerosis.

Though it once led to major adverse cardiovascular events, Kawasaki disease has evolved into a condition that is routinely overcome without significant morbidity.

Comparatively few patients treated for anaphylaxis in the emergency department are prescribed adrenaline autoinjectors, and many who do receive them either do not know how to properly use the device or fail to carry it with them at all times.

Injured workers and bystanders often suffer oily wounds in accidents that must be cleaned prior to surgery.

While a variety of surgical procedures can treat menorrhagia in premenopausal women, a recent study added a non-surgical alternative to the mix.

Women treated for depression with collaborative care showed fewer symptoms after treatment than women who received traditional care, according to a new study.

Just weeks after Australian researchers published data suggesting that testosterone replacement therapy does not ameliorate type 2 diabetes among hypogonadal men, a team of American researchers has unveiled a second study that suggests just the opposite.

Approximately 10,000 toddlers are prescribed Ritalin, Adderall and other drugs for ADHD, according to a report from the Centers for Disease Control and Prevention.

Perhaps, a very simple change in beverage choice could reduce the stroke burden in the United States.